UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16 23, 2022

Turning Point Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-38871	46-3826166
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)

10628 Science Center Drive, Ste. 200

San Diego, California

92121

(Address of Principal Executive Offices)

(Zip Code)

(858) 926-5251

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Trading Symbol~~TradingSymbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		TPTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5 1.0701. ~~Submission~~Entry ofinto ~~Matters to~~ a ~~Vote~~Material ofDefinitive ~~Security Holders~~Agreement.

On June 1623, 2022, Turning Point Therapeutics, Inc. (the “Company”) ~~held~~entered ~~its~~into ~~2022~~a ~~Annual~~strategic ~~Meeting~~collaboration ofagreement ~~Stockholders~~ (the “~~Annual Meeting~~Agreement”). Aswith ofThe ~~April 18,~~University ~~2022,~~of ~~the~~Texas ~~record~~M.D. ~~date~~Anderson ~~for~~Cancer ~~the~~Center ~~Annual~~(“MD ~~Meeting,~~Anderson”). ~~49,666,288~~Under ~~shares~~the terms of ~~common~~the ~~stock~~Agreement, ~~were~~the ~~outstanding~~Company ~~and~~will ~~entitled~~provide tofunding ~~vote~~and atsupport ~~the~~for ~~Annual~~preclinical ~~Meeting.~~and Aclinical ~~summary~~studies ofto ~~the~~be ~~matters~~conducted ~~voted upon~~ by ~~stockholders~~MD atAnderson ~~the~~in ~~Annual~~several ~~Meeting~~solid istumors, ~~set~~including ~~forth~~non-small ~~below.~~cell ~~Voting~~lung ~~results are~~cancers, ~~when~~gastrointestinal ~~applicable,~~malignancies ~~reported~~and byendocrine ~~rounding~~cancers ~~fractional share voting down to~~ (the ~~nearest round number~~“Studies”).

~~Proposal~~The initial focus of the Studies will be the Company’s lead drug candidate, repotrectinib, a next-generation kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors that is currently being studied in a registrational Phase 1:/2 ~~Election~~study (TRIDENT-1). The Studies will also include two additional drug candidates, elzovantinib (TPX-0022), a kinase inhibitor targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of ~~Directors~~patients with advanced solid tumors harboring genetic alterations in MET (SHIELD-1), and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer (FORGE-1).

~~The~~Pursuant ~~Company’s~~to ~~stockholders~~the ~~elected~~Agreement, the ~~two~~Company ~~persons~~has ~~listed~~agreed ~~below~~to asprovide ~~Class~~total funding in an amount of $10.0 ~~III~~million ~~directors~~for the performance of the Studies, ~~each~~such funding to ~~serve~~be ~~until~~provided ~~the~~in ~~Company’s~~increments ~~2025~~of ~~Annual~~$1.0 million ~~Meeting~~on ofa ~~Stockholders~~twice-yearly ~~and~~basis. ~~until~~The ~~their~~Studies ~~respective~~will ~~successors~~be ~~are~~overseen ~~duly~~by ~~elected~~a ~~and~~joint ~~qualified~~steering committee, orwhich ~~until~~will ~~their~~provide ~~earlier~~technical, ~~death~~scientific, ~~resignation~~clinical orand ~~removal.~~regulatory ~~The~~guidance, ~~final~~discuss ~~voting~~and ~~results~~approve ~~are~~study asbudgets, ~~follows:~~and monitor the progress of the Studies.

Name of Director Elected	Votes For	Votes Withheld	Broker Non-Votes
Mark J. Alles	31,342,218	13,093,788	2,099,409
Barbara W. Bodem	30,460,874	13,975,132	2,099,409

Under the terms of the Agreement, all Inventions will be solely owned by the Company, except with respect to the use of Proprietary Materials of MD Anderson that does not involve the use of the Company’s Study Drug or Proprietary Materials (each as defined in the Agreement).

~~Proposal~~The 2:term ~~Advisory~~of ~~Vote~~the onAgreement ~~Executive~~runs ~~Compensation~~five years or until the Studies are completed, whichever is later, unless terminated earlier in accordance with the terms set forth in the Agreement.

The ~~Company’s~~foregoing ~~stockholders~~description ~~approved,~~of onthe anmaterial ~~advisory~~terms ~~basis,~~of the ~~compensation~~Agreement ~~paid~~does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement, a copy of which the Company’s ~~named~~intends ~~executive~~to ~~officers~~file, with confidential terms redacted, with the Securities and Exchange Commission as ~~disclosed~~an inexhibit to the ~~proxy~~Company’s ~~statement.~~Quarterly ~~The~~Report ~~final~~on Form ~~voting~~10-Q ~~results~~for the ~~are~~quarterly asperiod ~~follows:~~ended June 30, 2022.

Votes For		Votes Against		Abstentions		Broker Non-Votes
29,055,338		13,851,055		1,529,613		2,099,409

Proposal 3: Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The final voting results are as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
46,459,043		64,181		12,191		—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

~~TURNING POINT THERAPEUTICS, INC.~~

TURNING POINT THERAPEUTICS, INC.

Date: June 21, 2022

/s/ Brian Sun

Date: June 24, 2022

/s/ Brian Sun

Senior Vice President and General Counsel

Filing Compare · Turning Point Therapeutics, Inc.